Abstract CN01-02: canSAR: An integrated cancer drug discovery informatics platform allowing systematic target evaluation.
Bissan Al‐Lazikani, Mishal N. Patel, Krishna C. Bulusu, Mark Halling‐Brown · Molecular Cancer Therapeutics · 2011
Abstract Large-scale systematic analyses of the underlying genetics and proteomics of cancer, as well as the systematic mapping of effects of RNAi and chemical screens on different cancer cells are empowering cancer drug discovery and paving the way to wider stratified medicine approaches to the treatment of cancer. However, this deluge of data poses an equally large challenge of effectively integrating such massive and heterogeneous datasets in a manner that allows researchers to benefit from a multidisciplinary view across different. To address this need, we have developed a multidisciplinary cancer platform, canSAR (http://cansar.icr.ac.uk). It integrates millions of experimental datapoints ranging from chemical and RNAi screening, to expression, drug ADMET studies and 3D structural complexes. In this presentation we describe canSAR and show examples of how it has been utilized in the knowledge-driven prioritization of targets for drug discovery. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr CN01-02.